Followers | 839 |
Posts | 120818 |
Boards Moderated | 13 |
Alias Born | 09/05/2002 |
Friday, July 29, 2022 2:07:50 PM
https://www.businesswire.com/news/home/20220728006068/en
This result is from Part A of the CHECKMATE-914 study, where Opdivo/Yervoy was compared to placebo. Part B of the same study, which compares Opdivo monotherapy to placebo, is still in progress.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent BMY News
- Bristol Myers Squibb to Participate in Citi’s 2024 Global Healthcare Conference • Business Wire • 11/26/2024 11:59:00 AM
- Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms • Business Wire • 11/19/2024 11:59:00 AM
- Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer • Business Wire • 11/15/2024 01:23:00 PM
- Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors • Business Wire • 11/15/2024 11:59:00 AM
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results • GlobeNewswire Inc. • 11/12/2024 09:05:51 PM
- Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024 • Business Wire • 11/11/2024 11:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 10:53:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 10:50:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 10:48:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 10:42:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/05/2024 10:41:22 PM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 11/05/2024 10:00:00 PM
- Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024 • Business Wire • 10/31/2024 08:16:00 PM
- Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 • Business Wire • 10/31/2024 10:59:00 AM
- Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 • Business Wire • 10/28/2024 10:59:00 AM
- U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 10/03/2024 09:35:00 PM
- Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies • GlobeNewswire Inc. • 09/30/2024 11:00:00 AM
- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults • Business Wire • 09/27/2024 11:38:00 PM
- Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting • Business Wire • 09/27/2024 03:06:00 PM
- U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults • Business Wire • 09/27/2024 01:05:00 AM
- New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis • Business Wire • 09/18/2024 10:59:00 AM
- Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma • Business Wire • 09/15/2024 12:55:00 PM
- Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024 • Business Wire • 09/12/2024 10:59:00 AM
- Bristol Myers Squibb Announces Dividend • Business Wire • 09/10/2024 09:45:00 PM
- Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms • Business Wire • 09/09/2024 10:59:00 AM
Avant Technologies' Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy • AVAI • Dec 4, 2024 8:00 AM
North Bay Resources Commences Fran Gold Winter Ore Shipment to Bishop Gold Mill, California • NBRI • Dec 2, 2024 9:07 AM
VAYK Reached Agreement on Terms to Acquire $1 Million Company for Disruptive Airbnb Strategy • VAYK • Dec 2, 2024 9:00 AM
ILUS Announces Completion of QIND Acquisition by Fusion Fuel (NASDAQ: HTOO) • ILUS • Nov 27, 2024 12:35 PM
Cannabix Technologies Receives Positive Testing Certification for Breath Logix Autonomous Alcohol Breathalyzer • BLO • Nov 26, 2024 8:48 AM
BioQuest, Inc. and BotMakers Expand AI Marketing Services with SpeedLeads XL and MarketScope XL. Bioquest Corp. and BotMakers, Inc. are Partnered to Expand AI Marketing Services with SpeedLead XL and MarketScope XL • BQST • Nov 26, 2024 8:00 AM